Inogen
INGN
220 hedge funds and large institutions have $2.5B invested in Inogen in 2017 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 80 increasing their positions, 80 reducing their positions, and 25 closing their positions.
52% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 25
23% more capital invested
Capital invested by funds: $2.03B → $2.5B (+$468M)
6% more funds holding
Funds holding: 208 → 220 (+12)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 80
9% less call options, than puts
Call options by funds: $5.42M | Put options by funds: $5.93M
2.51% less ownership
Funds ownership: 103.18% → 100.68% (-2.5%)
Top Buyers
| 1 |
Millennium Management
New York
|
+$25.2M |
| 2 |
BlackRock
New York
|
+$9.66M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$8.81M |
| 4 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$8.19M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$6.79M |
Top Sellers
INGN Hedge Fund Activity: Q4 2017 in Review
220 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Inogen (INGN) for Q4 2017, worth a combined $2.5B — up 23% from $2.03B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new INGN positions and 25 closed out — a net gain of 13 holders — while 80 added to existing stakes and 80 trimmed.
The largest buyer was Millennium Management, adding an estimated $25.2M. The largest seller was PFM Health Sciences, cutting an estimated $16.4M.
- 220 institutional investors held Inogen (INGN) as of Q4 2017, up from 208 in Q3 2017.
- Funds reported $2.5B of Inogen stock for Q4 2017, up 23% quarter-over-quarter.
- 38 funds opened new Inogen positions in Q4 2017 and 25 closed out, a net change of +13 holders.
- The largest Inogen buyer in Q4 2017 was Millennium Management, an estimated $25.2M added.
- The largest Inogen seller in Q4 2017 was PFM Health Sciences, an estimated $16.4M sold.
Based on aggregated 13F filings for Q4 2017.